Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722292 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01722292 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 26 participants.
The verdict
NCT01722292, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to find a recommended dose of LY2940680 that can be safely given in combination with etoposide and carboplatin followed by LY2940680 alone in participants with extensive-disease small cell lung cancer. The study will also compare progression-free survival in participants who are administered etoposide, carboplatin and LY2940680 followed by LY2940680 alone versus etoposide, carboplatin, and placebo followed by placebo alone.
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Etoposide
- DRUG LY2940680
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01722292
The ClinicalTrials.gov registry entry for NCT01722292 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01722292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01722292 about?
NCT01722292 is a clinical study titled "A Study of LY2940680 in Small Cell Lung Cancer". The purpose of this study is to find a recommended dose of LY2940680 that can be safely given in combination with etoposide and carboplatin followed by LY2940680 alone in participants with extensive-disease small cell lung cancer. The study will also compare progression-free survival in participants...
What is the current status of trial NCT01722292?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-01. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01722292?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Etoposide (DRUG), LY2940680 (DRUG).
Who is sponsoring clinical trial NCT01722292?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.